EUVIMEDObjevte EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Vincristine-induced adverse events related to body weight in dogs treated for lymphoma

Keira E Sztukowski iD, Zachary Yaufman, Matthew R Cook, Turi K Aarnes, Brian D Husbands iD

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.17063 ↗

At a glance

Multizentrische Studie in Journal of Veterinary Internal Medicine, 2024. Written by Keira E Sztukowski and 4 co-authors. Institution: Department of Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA. Major MEDLINE topics: Dog Diseases, Vincristine, Lymphoma, Body Weight. Cited 3 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Traditional dosing of chemotherapy drugs based on body surface area may overdose small dogs, leading to an increased frequency of adverse events (AEs). Hypothesis/Objectives Evaluate the frequency of hematologic and gastrointestinal AEs in dogs with newly diagnosed lymphoma treated with vincristine weighing ≤15 kg in comparison to dogs weighing >15 kg. We hypothesized that dogs weighing ≤15 kg would experience a higher frequency of AEs. Animals One hundred and thirty-eight dogs with newly diagnosed lymphoma were treated with vincristine.

Methods

A multicenter retrospective study reviewing hematologic data and medical record information. Complete blood counts were performed no more than 24 hours before vincristine administration and then between 4 and 8 days post-administration. Data were evaluated using logistic regression or ordinal logistic regression.

Results

Thirty-eight dogs weighing ≤15 kg and 100 dogs weighing >15 kg were included. The median vincristine dose for both groups was 0.6 mg/m2. Seventeen (12.3%) instances of neutropenia occurred with no significant difference in overall frequency or grade between groups. Thirty initially asymptomatic substage A dogs (29.4%) experienced gastrointestinal AEs. Because of the widespread use of gastrointestinal supportive care medications, statistical comparison between groups could not be performed. Seven instances of hospitalization occurred (5.0%) and the risk of hospitalization did not differ significantly between groups (P = .37). Conclusions and Clinical Importance Vincristine dosed at ≤0.6 mg/m2 does not increase the risk of hematologic AEs in dogs weighing ≤15 kg.

Subjects

MeSH terms (MEDLINE)

Dog DiseasesVincristineLymphomaBody WeightAntineoplastic Agents, PhytogenicAnimalsDogsRetrospective StudiesMaleFemaleNeutropenia

Author keywords

BSAadverse eventscaninechemotherapylymphomaneutropeniavincristine

Substances

VincristineAntineoplastic Agents, Phytogenic

Authors and institutions

  • Department of Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA.
  • Nashville Veterinary Specialists, Nashville, Tennessee, USA.

ORCID profiles: Keira E Sztukowski, Brian D Husbands

Cite

APA

Sztukowski, K. E., Yaufman, Z., Cook, M. R., Aarnes, T. K., & Husbands, B. D. (2024). Vincristine-induced adverse events related to body weight in dogs treated for lymphoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17063

Vancouver

Sztukowski KE, Yaufman Z, Cook MR, Aarnes TK, Husbands BD. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17063

BibTeX
@article{Sztukowski2024,
  author = {Sztukowski, Keira E and Yaufman, Zachary and Cook, Matthew R and Aarnes, Turi K and Husbands, Brian D},
  title = {Vincristine-induced adverse events related to body weight in dogs treated for lymphoma},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.17063}
}
Start for free →